메뉴 건너뛰기




Volumn 1818, Issue 12, 2012, Pages 2950-2957

HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain

Author keywords

Drug resistance; Fusion inhibitors; gp41; HIV 1; Membrane binding; Mutation

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C34 PEPTIDE; ENFUVIRTIDE; GLYCOPROTEIN GP 41; UNCLASSIFIED DRUG;

EID: 84865335285     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2012.07.020     Document Type: Article
Times cited : (32)

References (55)
  • 1
    • 0032546844 scopus 로고    scopus 로고
    • The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
    • R. Wyatt, and J.G. Sodroski The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens Science 280 1998 1884 1888
    • (1998) Science , vol.280 , pp. 1884-1888
    • Wyatt, R.1    Sodroski, J.G.2
  • 3
    • 0037301373 scopus 로고    scopus 로고
    • Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites
    • Y. He, R. Vassell, M. Zaitseva, N. Nguyen, Z. Yang, Y. Weng, and C.D. Weiss Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites J. Virol. 77 2003 1666 1671
    • (2003) J. Virol. , vol.77 , pp. 1666-1671
    • He, Y.1    Vassell, R.2    Zaitseva, M.3    Nguyen, N.4    Yang, Z.5    Weng, Y.6    Weiss, C.D.7
  • 4
    • 0031010455 scopus 로고    scopus 로고
    • Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell fusion - Structure-function study
    • Y. Kliger, A. Aharoni, D. Rapaport, P. Jones, R. Blumenthal, and Y. Shai Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell fusion - structure-function study J. Biol. Chem. 272 1997 13496 13505
    • (1997) J. Biol. Chem. , vol.272 , pp. 13496-13505
    • Kliger, Y.1    Aharoni, A.2    Rapaport, D.3    Jones, P.4    Blumenthal, R.5    Shai, Y.6
  • 6
    • 0030970693 scopus 로고    scopus 로고
    • Core structure of gp41 from the HIV envelope glycoprotein
    • D.C. Chan, D. Fass, J.M. Berger, and P.S. Kim Core structure of gp41 from the HIV envelope glycoprotein Cell 89 1997 263 273
    • (1997) Cell , vol.89 , pp. 263-273
    • Chan, D.C.1    Fass, D.2    Berger, J.M.3    Kim, P.S.4
  • 8
    • 0031959601 scopus 로고    scopus 로고
    • Capture of an early fusion-active comformation of HIV-1 gp41
    • R. Furuta, C.T. Wild, Y. Weng, and C.D. Weiss Capture of an early fusion-active comformation of HIV-1 gp41 Nat. Struct. Biol. 5 1998 276 279
    • (1998) Nat. Struct. Biol. , vol.5 , pp. 276-279
    • Furuta, R.1    Wild, C.T.2    Weng, Y.3    Weiss, C.D.4
  • 9
    • 0034645796 scopus 로고    scopus 로고
    • Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation
    • Y. Kliger, and Y. Shai Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation J. Mol. Biol. 295 2000 163 168
    • (2000) J. Mol. Biol. , vol.295 , pp. 163-168
    • Kliger, Y.1    Shai, Y.2
  • 10
    • 0027203897 scopus 로고
    • Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41
    • S. Jiang, K. Lin, N. Strick, and A.R. Neurath Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41 Biochem. Biophys. Res. Commun. 195 1993 533 538
    • (1993) Biochem. Biophys. Res. Commun. , vol.195 , pp. 533-538
    • Jiang, S.1    Lin, K.2    Strick, N.3    Neurath, A.R.4
  • 12
    • 0028575843 scopus 로고
    • Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex
    • C. Wild, J.W. Dubay, T. Greenwell, T. Baird Jr., T.G. Oas, C. McDanal, E. Hunter, and T. Matthews Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex Proc. Natl. Acad. Sci. U. S. A. 91 1994 12676 12680
    • (1994) Proc. Natl. Acad. Sci. U. S. A. , vol.91 , pp. 12676-12680
    • Wild, C.1    Dubay, J.W.2    Greenwell, T.3    Baird, Jr.T.4    Oas, T.G.5    McDanal, C.6    Hunter, E.7    Matthews, T.8
  • 13
    • 0027692502 scopus 로고
    • A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion
    • C. Wild, T. Greenwell, and T. Matthews A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion AIDS Res. Hum. Retroviruses 9 1993 1051 1053
    • (1993) AIDS Res. Hum. Retroviruses , vol.9 , pp. 1051-1053
    • Wild, C.1    Greenwell, T.2    Matthews, T.3
  • 14
    • 0031441562 scopus 로고    scopus 로고
    • A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein
    • M. Lu, and P.S. Kim A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein J. Biomol. Struct. Dyn. 15 1997 465 471
    • (1997) J. Biomol. Struct. Dyn. , vol.15 , pp. 465-471
    • Lu, M.1    Kim, P.S.2
  • 15
    • 0026465468 scopus 로고
    • A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition
    • C. Wild, T. Oas, C. McDanal, D. Bolognesi, and T. Matthews A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition Proc. Natl. Acad. Sci. U. S. A. 89 1992 10537 10541
    • (1992) Proc. Natl. Acad. Sci. U. S. A. , vol.89 , pp. 10537-10541
    • Wild, C.1    Oas, T.2    McDanal, C.3    Bolognesi, D.4    Matthews, T.5
  • 16
    • 0038671938 scopus 로고    scopus 로고
    • The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation
    • J.J. Dwyer, A. Hasan, K.L. Wilson, J.M. White, T.J. Matthews, and M.K. Delmedico The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation Biochemistry 42 2003 4945 4953
    • (2003) Biochemistry , vol.42 , pp. 4945-4953
    • Dwyer, J.J.1    Hasan, A.2    Wilson, K.L.3    White, J.M.4    Matthews, T.J.5    Delmedico, M.K.6
  • 17
    • 67650745033 scopus 로고    scopus 로고
    • The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket
    • M. Gochin The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket J. Med. Chem. 2009 4338 4344
    • (2009) J. Med. Chem. , pp. 4338-4344
    • Gochin, M.1
  • 18
    • 0032433685 scopus 로고    scopus 로고
    • Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
    • D.C. Chan, C.T. Chutkowski, and P.S. Kim Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc. Natl. Acad. Sci. U. S. A. 95 1998 15613 15617
    • (1998) Proc. Natl. Acad. Sci. U. S. A. , vol.95 , pp. 15613-15617
    • Chan, D.C.1    Chutkowski, C.T.2    Kim, P.S.3
  • 19
    • 0032850583 scopus 로고    scopus 로고
    • Inhibition of HIV-1 infectivity by the gp41 core: Role of a conserved hydrophobic cavity in membrane fusion
    • H. Ji, W. Shu, T. Burling, S. Jiang, and M. Lu Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion J. Virol. 73 1999 8578 8586
    • (1999) J. Virol. , vol.73 , pp. 8578-8586
    • Ji, H.1    Shu, W.2    Burling, T.3    Jiang, S.4    Lu, M.5
  • 20
    • 57649155175 scopus 로고    scopus 로고
    • Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors
    • Z. Qi, W. Shi, N. Xue, C. Pan, W. Jing, K. Liu, and S. Jiang Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors J. Biol. Chem. 283 2008 30376 30384
    • (2008) J. Biol. Chem. , vol.283 , pp. 30376-30384
    • Qi, Z.1    Shi, W.2    Xue, N.3    Pan, C.4    Jing, W.5    Liu, K.6    Jiang, S.7
  • 21
    • 34248155890 scopus 로고    scopus 로고
    • HIV gp41 C-terminal heptad repeat contains multifunctional domains: Relation to mechanisms of action of anti-HIV peptides
    • S. Liu, W. Jing, B. Cheung, H. Lu, J. Sun, X. Yan, J. Niu, J. Farmar, S. Wu, and S. Jiang HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides J. Biol. Chem. 282 2007 9612 9620
    • (2007) J. Biol. Chem. , vol.282 , pp. 9612-9620
    • Liu, S.1    Jing, W.2    Cheung, B.3    Lu, H.4    Sun, J.5    Yan, X.6    Niu, J.7    Farmar, J.8    Wu, S.9    Jiang, S.10
  • 22
    • 15744393651 scopus 로고    scopus 로고
    • Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120
    • S. Liu, H. Lu, Y. Xu, S. Wu, and S. Jiang Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120 J. Biol. Chem. 280 2005 11259 11273
    • (2005) J. Biol. Chem. , vol.280 , pp. 11259-11273
    • Liu, S.1    Lu, H.2    Xu, Y.3    Wu, S.4    Jiang, S.5
  • 23
    • 3042606321 scopus 로고    scopus 로고
    • Peptide inhibitors of virus-cell fusion: Enfuvirtide as a case study in clinical discovery and development
    • D.A. Cooper, and J.M. Lange Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development Lancet Infect. Dis. 4 2004 426 436
    • (2004) Lancet Infect. Dis. , vol.4 , pp. 426-436
    • Cooper, D.A.1    Lange, J.M.2
  • 24
    • 0038187684 scopus 로고    scopus 로고
    • Novel therapies based on mechanisms of HIV-1 cell entry, N.Engl
    • J.M. Kilby, and J.J. Eron Novel therapies based on mechanisms of HIV-1 cell entry, N.Engl J. Med. 348 2003 2228 2238
    • (2003) J. Med. , vol.348 , pp. 2228-2238
    • Kilby, J.M.1    Eron, J.J.2
  • 28
    • 0031883832 scopus 로고    scopus 로고
    • Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides
    • L.T. Rimsky, D.C. Shugars, and T.J. Matthews Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides J. Virol. 72 1998 986 993
    • (1998) J. Virol. , vol.72 , pp. 986-993
    • Rimsky, L.T.1    Shugars, D.C.2    Matthews, T.J.3
  • 29
    • 63149093637 scopus 로고    scopus 로고
    • HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide
    • N. Ray, L.A. Blackburn, and R.W. Doms HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide J. Virol. 83 2009 2989 2995
    • (2009) J. Virol. , vol.83 , pp. 2989-2995
    • Ray, N.1    Blackburn, L.A.2    Doms, R.W.3
  • 30
    • 33947417638 scopus 로고    scopus 로고
    • Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors
    • N. Ray, J.E. Harrison, L.A. Blackburn, J.N. Martin, S.G. Deeks, and R.W. Doms Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors J. Virol. 81 2007 3240 3250
    • (2007) J. Virol. , vol.81 , pp. 3240-3250
    • Ray, N.1    Harrison, J.E.2    Blackburn, L.A.3    Martin, J.N.4    Deeks, S.G.5    Doms, R.W.6
  • 31
    • 0042706375 scopus 로고    scopus 로고
    • HIV-1 resistance to the gp41-dependent fusion inhibitor C-34
    • M. Armand-Ugon, A. Gutierrez, B. Clotet, and J.A. Este HIV-1 resistance to the gp41-dependent fusion inhibitor C-34 Antiviral Res. 59 2003 137 142
    • (2003) Antiviral Res. , vol.59 , pp. 137-142
    • Armand-Ugon, M.1    Gutierrez, A.2    Clotet, B.3    Este, J.A.4
  • 32
    • 0037936885 scopus 로고    scopus 로고
    • C-terminal octylation rescues an inactive T20 mutant: Implications for the mechanism of HIV/SIV-induced membrane fusion
    • S.G. Peisajovich, S.A. Gallo, R. Blumenthal, and Y. Shai C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIV-induced membrane fusion J. Biol. Chem. 278 2003 21012 21017
    • (2003) J. Biol. Chem. , vol.278 , pp. 21012-21017
    • Peisajovich, S.G.1    Gallo, S.A.2    Blumenthal, R.3    Shai, Y.4
  • 34
    • 0014109212 scopus 로고
    • Spectroscopic determination of tryptophan and tyrosine in proteins
    • H. Edelhoch Spectroscopic determination of tryptophan and tyrosine in proteins Biochemistry 6 1967 1948 1954
    • (1967) Biochemistry , vol.6 , pp. 1948-1954
    • Edelhoch, H.1
  • 35
    • 0034023726 scopus 로고    scopus 로고
    • Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41
    • Y. Weng, Z. Yang, and C.D. Weiss Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41 J. Virol. 74 2000 5368 5372
    • (2000) J. Virol. , vol.74 , pp. 5368-5372
    • Weng, Y.1    Yang, Z.2    Weiss, C.D.3
  • 36
    • 16244367157 scopus 로고    scopus 로고
    • Human immunodeficiency virus (HIV) gp41 escape mutants: Cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120
    • E. Desmezieres, N. Gupta, R. Vassell, Y. He, K. Peden, L. Sirota, Z. Yang, P. Wingfield, and C.D. Weiss Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120 J. Virol. 79 2005 4774 4781
    • (2005) J. Virol. , vol.79 , pp. 4774-4781
    • Desmezieres, E.1    Gupta, N.2    Vassell, R.3    He, Y.4    Peden, K.5    Sirota, L.6    Yang, Z.7    Wingfield, P.8    Weiss, C.D.9
  • 37
    • 84862927851 scopus 로고    scopus 로고
    • Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket
    • X. Yu, L. Lu, L. Cai, P. Tong, S. Tan, P. Zou, F. Meng, Y.H. Chen, and S. Jiang Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket J. Virol. 86 2012 589 593
    • (2012) J. Virol. , vol.86 , pp. 589-593
    • Yu, X.1    Lu, L.2    Cai, L.3    Tong, P.4    Tan, S.5    Zou, P.6    Meng, F.7    Chen, Y.H.8    Jiang, S.9
  • 38
    • 0034701058 scopus 로고    scopus 로고
    • Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides
    • W. Shu, J. Liu, H. Ji, L. Radigan, S. Jiang, and M. Lu Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides Biochemistry 39 2000 1634 1642
    • (2000) Biochemistry , vol.39 , pp. 1634-1642
    • Shu, W.1    Liu, J.2    Ji, H.3    Radigan, L.4    Jiang, S.5    Lu, M.6
  • 39
    • 0346729750 scopus 로고    scopus 로고
    • Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: Applicable for identification of the HIV-1 fusion inhibitors
    • S. Liu, Q. Zhao, and S. Jiang Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors Peptide 24 2003 1303 1313
    • (2003) Peptide , vol.24 , pp. 1303-1313
    • Liu, S.1    Zhao, Q.2    Jiang, S.3
  • 40
    • 7244253012 scopus 로고    scopus 로고
    • N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion
    • S. Jiang, H. Lu, S. Liu, Q. Zhao, Y. He, and A.K. Debnath N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion Antimicrob. Agents Chemother. 48 2004 4349 4359
    • (2004) Antimicrob. Agents Chemother. , vol.48 , pp. 4349-4359
    • Jiang, S.1    Lu, H.2    Liu, S.3    Zhao, Q.4    He, Y.5    Debnath, A.K.6
  • 41
    • 77951216905 scopus 로고    scopus 로고
    • 3-Hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: A potential microbicide for preventing sexual transmission of HIV-1
    • L. Li, L. He, S. Tan, X. Guo, H. Lu, Z. Qi, C. Pan, X. An, S. Jiang, and S. Liu 3-Hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1 Antimicrob. Agents Chemother. 54 2010 1700 1711
    • (2010) Antimicrob. Agents Chemother. , vol.54 , pp. 1700-1711
    • Li, L.1    He, L.2    Tan, S.3    Guo, X.4    Lu, H.5    Qi, Z.6    Pan, C.7    An, X.8    Jiang, S.9    Liu, S.10
  • 42
    • 67749147470 scopus 로고    scopus 로고
    • Combinations of the first and next generation HIV fusion inhibitors exhibit highly potent synergistic effect against enfuvirtide-sensitive and resistant HIV-1 strains
    • C. Pan, L. Cai, H. Lu, Z. Qi, and S. Jiang Combinations of the first and next generation HIV fusion inhibitors exhibit highly potent synergistic effect against enfuvirtide-sensitive and resistant HIV-1 strains J. Virol. 83 2009 7862 7872
    • (2009) J. Virol. , vol.83 , pp. 7862-7872
    • Pan, C.1    Cai, L.2    Lu, H.3    Qi, Z.4    Jiang, S.5
  • 43
    • 33748794547 scopus 로고    scopus 로고
    • Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
    • T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
    • (2006) Pharmacol. Rev. , vol.58 , pp. 621-681
    • Chou, T.C.1
  • 44
    • 0021118703 scopus 로고
    • Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
    • T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
    • (1984) Adv. Enzyme Regul. , vol.22 , pp. 27-55
    • Chou, T.C.1    Talalay, P.2
  • 45
    • 0031798443 scopus 로고    scopus 로고
    • Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41
    • Y. Weng, and C.D. Weiss Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41 J. Virol. 72 1998 9676 9682
    • (1998) J. Virol. , vol.72 , pp. 9676-9682
    • Weng, Y.1    Weiss, C.D.2
  • 46
    • 0032850583 scopus 로고    scopus 로고
    • Inhibition of HIV-1 infectivity by the gp41 core: Role of a conserved hydrophobic cavity in membrane fusion
    • H. Ji, W. Shu, T. Burling, S. Jiang, and M. Lu Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion J. Virol. 73 1999 8578 8586
    • (1999) J. Virol. , vol.73 , pp. 8578-8586
    • Ji, H.1    Shu, W.2    Burling, T.3    Jiang, S.4    Lu, M.5
  • 49
    • 0028953212 scopus 로고
    • The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure
    • C. Wild, T. Greenwell, D. Shugars, L. Rimsky-Clarke, and T. Matthews The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure AIDS Res. Hum. Retroviruses 11 1995 323 325
    • (1995) AIDS Res. Hum. Retroviruses , vol.11 , pp. 323-325
    • Wild, C.1    Greenwell, T.2    Shugars, D.3    Rimsky-Clarke, L.4    Matthews, T.5
  • 51
    • 79952781156 scopus 로고    scopus 로고
    • In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor
    • Z. Liu, M. Shan, L. Li, L. Lu, S. Meng, C. Chen, Y. He, S. Jiang, and L. Zhang In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor J. Biol. Chem. 286 2010 3277 3287
    • (2010) J. Biol. Chem. , vol.286 , pp. 3277-3287
    • Liu, Z.1    Shan, M.2    Li, L.3    Lu, L.4    Meng, S.5    Chen, C.6    He, Y.7    Jiang, S.8    Zhang, L.9
  • 52
    • 80055013474 scopus 로고    scopus 로고
    • Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function
    • D. Eggink, I. Bontjer, J.P. Langedijk, B. Berkhout, and R.W. Sanders Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function J. Virol. 85 2011 10785 10797
    • (2011) J. Virol. , vol.85 , pp. 10785-10797
    • Eggink, D.1    Bontjer, I.2    Langedijk, J.P.3    Berkhout, B.4    Sanders, R.W.5
  • 53
    • 84857363079 scopus 로고    scopus 로고
    • Is there a future for antiviral fusion inhibitors?
    • B. Berkhout, D. Eggink, and R.W. Sanders Is there a future for antiviral fusion inhibitors? Curr. Opin. Virol. 2 2012 50 59
    • (2012) Curr. Opin. Virol. , vol.2 , pp. 50-59
    • Berkhout, B.1    Eggink, D.2    Sanders, R.W.3
  • 54
    • 0030162962 scopus 로고    scopus 로고
    • Therapy of HIV infections: Problems and prospects
    • D.D. Ho Therapy of HIV infections: problems and prospects Bull. N. Y. Acad. Med. 73 1996 37 45
    • (1996) Bull. N. Y. Acad. Med. , vol.73 , pp. 37-45
    • Ho, D.D.1
  • 55
    • 63149114263 scopus 로고    scopus 로고
    • Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors
    • C. Pan, H. Lu, Z. Qi, and S. Jiang Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors AIDS 23 2009 639 641
    • (2009) AIDS , vol.23 , pp. 639-641
    • Pan, C.1    Lu, H.2    Qi, Z.3    Jiang, S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.